Skip to main content

Table 1 Demographics and Clinical Characteristics of Study Patients (N = 168)

From: BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study

 

BRCAm

n = 15

BRCAwt

n = 25

p-Value*

Untested

n = 128

p-Value**

Year of Ovarian Cancer Diagnosis

 Median (IQR)

2007 (2004–2009)

2008 (2005–2010)

0.305

2004 (2000–2007)

0.027

Year of PSR Diagnosis

 Median (IQR)

2008 (2006–2011)

2010 (2008–2012)

0.201

2006 (2003–2009)

0.043

Age at Recurrence, Years

 Median age (IQR)

58 (48–64)

57 (50–63)

0.900

63 (54–71)

0.052

 Mean age ± SD

56 ± 11.0

56 ± 9.7

0.903

63 ± 12.7

0.033

 Age group

     

  <60 years

8 (53.3 %)

15 (60.0 %)

0.231

50 (39.1 %)

0.039

  60–74 years

5 (33.3 %)

10 (40.0 %)

55 (43.0 %)

  ≥75 years

2 (13.3 %)

0

23 (18.0 %)

Ethnicity

 White

8 (53 %)

18 (72 %)

0.138

84 (66 %)

0.372

 Hispanic

2 (13 %)

0 (0 %)

7 (5 %)

 Other

0 (0 %)

2 (8 %)

6 (5 %)

 Unknown

5 (33 %)

5 (20 %)

31 (24 %)

Family History of Hereditary Breast or Ovarian Cancer

 No family history

0 (0 %)

14 (56 %)

<0.001

103 (80 %)

<0.001

 Familial risk

15 (100 %)

11 (44 %)

25 (20 %)

Personal History of Breast Cancer

 No history

10 (67 %)

22 (88 %)

0.126

121 (95 %)

0.003

 History of breast cancer

5 (33 %)

3 (12 %)

7 (5 %)

Stage at Ovarian Cancer Diagnosis

 ≤2

2 (13.3 %)

5 (20 %)

0.900

21 (16.4 %)

0.917

 ≥3

10 (66.7 %)

15 (60 %)

87 (68.0 %)

 Unknown

3 (20 %)

5 (20 %)

20 (15.6 %)

Pathology

 Serous

10 (66.7 %)

18 (72 %)

0.910

77 (60.2 %)

0.759

 Adenocarcinoma

1 (6.7 %)

1 (4 %)

14 (10.9 %)

 Endometrioid

0

1 (4 %)

11 (8.6 %)

 Other

4 (26.7 %)

5 (20 %)

26 (20.3 %)

Tumor Histologic Grade at Ovarian Cancer Diagnosis

 1 and 2

2 (13.3 %)

3 (12 %)

0.847

15 (11.7 %)

0.855

 3

7 (46.7 %)

8 (32 %)

68 (53.1 %)

 4

2 (13.3 %)

5 (20 %)

12 (9.4 %)

 Unknown

4 (26.7 %)

9 (36 %)

33 (25.8 %)

Primary Tumor Site

 Ovary

12 (80 %)

20 (80 %)

0.574

113 (88.3 %)

0.363

 Peritoneum

3 (20 %)

3 (12 %)

11 (8.6 %)

 Fallopian tube

0 (0 %)

2 (8 %)

4 (3.1 %)

Ca-125 at Recurrence (Highest Value ±30 days), U/mL

 Median Ca-125 (IQR)

195 (82–274)

49.5 (36.5–178)

0.218

90 (34–343)

0.549

 ECOG score

 Median ECOG (IQR)

1 (0–1)

0 (0–1)

0.457

1 (0–1)

0.634

 ECOG group

     

  ≤2

6 (40 %)

14 (56 %)

0.514

34 (26.6 %)

0.490

  ≥3

0

0

2 (1.6 %)

 Unknown

9 (60 %)

11 (44 %)

92 (71.9 %)

Initial Treatment at Ovarian Cancer Diagnosis

 Chemotherapy

7 (46.7 %)

12 (48 %)

0.547

50 (39.1 %)

0.504

 Neoadjuvant chemotherapy

4 (26.7 %)

3 (12 %)

11 (8.6 %)

 Radiation therapy

0

0

2 (1.6 %)

 Primary debulking or cytoreductive surgery

9 (60 %)

23 (92 %)

110 (86 %)

 Missing

0

0

1 (0.8 %)

Duration of Follow-up, Days

 Median (IQR)

1064 (656–2231)

981.5 (434–1546)

0.419

490 (219–1015)

0.005

  1. *BRCAm vs. BRCAwt Fisher’s exact test for categorical variables, Wilcoxon rank-sum or t-test for continuous variables; **BRCAm vs. Untested Fisher’s exact test for categorical variables, Wilcoxon rank-sum or t-test for continuous variables